UK cost body backs pricey Gilead hepatitis pill for some patients

August 15, 2014 12:14 AM

22 0

LONDON, Aug 15 (Reuters) - Gilead Sciences' expensive new hepatitis C pill has been endorsed for use in certain patients by Britain's healthcare cost-effectiveness watchdog, after the U.S. firm provided more information.

The National Institute for Health and Care Excellence (NICE) had told Gilead in June to come back with more data to support the use of Sovaldi, a drug whose sky-high U.S. price of $1,000 per pill has sparked fierce debate over costly modern medicines.

Read more

To category page